company background image
BCEL

Atreca NasdaqGS:BCEL Stock Report

Last Price

US$2.49

Market Cap

US$96.1m

7D

15.8%

1Y

-57.7%

Updated

16 Aug, 2022

Data

Company Financials +
BCEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BCEL Stock Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.

Atreca Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atreca
Historical stock prices
Current Share PriceUS$2.49
52 Week HighUS$7.00
52 Week LowUS$1.51
Beta0.68
1 Month Change20.87%
3 Month Change42.29%
1 Year Change-57.65%
3 Year Change-87.91%
5 Year Changen/a
Change since IPO-86.21%

Recent News & Updates

Aug 08

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca press release (NASDAQ:BCEL): Q2 GAAP EPS of -$0.72 misses by $0.02. cash and cash equivalents and investments totaled $101.7 million.

Jun 18
Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

BCELUS BiotechsUS Market
7D15.8%1.8%4.5%
1Y-57.7%-22.2%-8.9%

Return vs Industry: BCEL underperformed the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: BCEL underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is BCEL's price volatile compared to industry and market?
BCEL volatility
BCEL Average Weekly Movement16.0%
Biotechs Industry Average Movement12.5%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: BCEL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: BCEL's weekly volatility has decreased from 33% to 16% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010105John Orwinhttps://www.atreca.com

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients.

Atreca Fundamentals Summary

How do Atreca's earnings and revenue compare to its market cap?
BCEL fundamental statistics
Market CapUS$96.09m
Earnings (TTM)-US$109.63m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BCEL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$109.63m
Earnings-US$109.63m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.84
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BCEL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BCEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCEL?

Other financial metrics that can be useful for relative valuation.

BCEL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.6x
PEG Ration/a

Price to Book Ratio vs Peers

How does BCEL's PB Ratio compare to its peers?

BCEL PB Ratio vs Peers
The above table shows the PB ratio for BCEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.6x
ANVS Annovis Bio
2.8x-13.1%US$98.5m
SRZN Surrozen
1.2x-20.9%US$103.6m
RZLT Rezolute
2x32.6%US$104.1m
AQB AquaBounty Technologies
0.5x-3.6%US$99.6m
BCEL Atreca
0.8x4.8%US$96.1m

Price-To-Book vs Peers: BCEL is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.6x).


Price to Earnings Ratio vs Industry

How does BCEL's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: BCEL is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (2x)


Price to Book Ratio vs Fair Ratio

What is BCEL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCEL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BCEL's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BCEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BCEL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BCEL's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Atreca forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


4.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCEL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCEL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCEL is forecast to have no revenue next year.

High Growth Revenue: BCEL is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCEL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Atreca performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-26.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BCEL is currently unprofitable.

Growing Profit Margin: BCEL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BCEL is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare BCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: BCEL has a negative Return on Equity (-95.16%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Atreca's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BCEL's short term assets ($109.6M) exceed its short term liabilities ($13.5M).

Long Term Liabilities: BCEL's short term assets ($109.6M) exceed its long term liabilities ($62.2M).


Debt to Equity History and Analysis

Debt Level: BCEL is debt free.

Reducing Debt: BCEL has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCEL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BCEL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 24.6% each year


Discover healthy companies

Dividend

What is Atreca current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCEL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BCEL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

John Orwin (57 yo)

4.33yrs

Tenure

US$4,192,126

Compensation

Mr. John A. Orwin has been President, Chief Executive Officer and Director at Atreca, Inc. since April 19, 2018. Mr. Orwin has been a Director of Seagen Inc. since January 13, 2014. Prior to joining Atreca...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD4.19M) is above average for companies of similar size in the US market ($USD759.98K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BCEL's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: BCEL's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.


Top Shareholders

Company Information

Atreca, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Atreca, Inc.
  • Ticker: BCEL
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$96.093m
  • Shares outstanding: 38.59m
  • Website: https://www.atreca.com

Number of Employees


Location

  • Atreca, Inc.
  • 835 Industrial Road
  • Suite 400
  • South San Francisco
  • California
  • 94070
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.